Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
Tempus AI (NASDAQ: TEM) announced a collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to develop a real-world multimodal, deidentified follicular lymphoma (FL) data library within Tempus' Lens platform. The initiative aims to accelerate the development of targeted therapies for FL patients through AI-driven insights.
The collaboration will initially focus on generating multimodal FL data for POD24 patients - those experiencing disease progression within 24 months of treatment - through a Tempus-sponsored study. The data library is expected to enhance researchers' understanding of FL biology and support the development of precision medicines by providing insights into the disease's heterogeneity.
The partnership combines IFLI's specialized FL focus with Tempus' AI-enabled solutions to create a centralized database that will be accessible to researchers and professionals working to combat follicular lymphoma.
Tempus AI (NASDAQ: TEM) ha annunciato una collaborazione con l'Institute for Follicular Lymphoma Innovation (IFLI) per sviluppare una biblioteca di dati multimodali e deidentificati sul linfoma follicolare (FL) all'interno della piattaforma Lens di Tempus. L'iniziativa mira ad accelerare lo sviluppo di terapie mirate per i pazienti affetti da FL attraverso approfondimenti guidati dall'IA.
La collaborazione si concentrerà inizialmente sulla generazione di dati multimodali sul FL per i pazienti POD24 - quelli che manifestano una progressione della malattia entro 24 mesi dal trattamento - attraverso uno studio sponsorizzato da Tempus. Si prevede che la biblioteca di dati migliori la comprensione della biologia del FL da parte dei ricercatori e supporti lo sviluppo di medicinali di precisione fornendo informazioni sulla eterogeneità della malattia.
Il partenariato combina il focus specializzato di IFLI sul FL con le soluzioni abilitate all'IA di Tempus per creare un database centralizzato che sarà accessibile a ricercatori e professionisti impegnati nella lotta contro il linfoma follicolare.
Tempus AI (NASDAQ: TEM) anunció una colaboración con el Institute for Follicular Lymphoma Innovation (IFLI) para desarrollar una biblioteca de datos multimodal y desidentificada sobre el linfoma folicular (FL) dentro de la plataforma Lens de Tempus. La iniciativa tiene como objetivo acelerar el desarrollo de terapias dirigidas para pacientes con FL a través de conocimientos impulsados por IA.
La colaboración se centrará inicialmente en generar datos multimodales sobre FL para pacientes POD24 - aquellos que experimentan progresión de la enfermedad dentro de los 24 meses posteriores al tratamiento - a través de un estudio patrocinado por Tempus. Se espera que la biblioteca de datos mejore la comprensión de los investigadores sobre la biología del FL y apoye el desarrollo de medicamentos de precisión al proporcionar información sobre la heterogeneidad de la enfermedad.
La asociación combina el enfoque especializado de IFLI en FL con las soluciones habilitadas por IA de Tempus para crear una base de datos centralizada que estará accesible para investigadores y profesionales que trabajan para combatir el linfoma folicular.
템퍼스 AI (NASDAQ: TEM)는 모낭 림프종 혁신 연구소 (IFLI)와 협력하여 템퍼스의 렌즈 플랫폼 내에서 실제 세계의 다중 모드, 비식별 모낭 림프종 (FL) 데이터 라이브러리를 개발한다고 발표했습니다. 이 이니셔티브는 AI 기반 통찰력을 통해 FL 환자를 위한 표적 치료제 개발을 가속화하는 것을 목표로 합니다.
협력은 초기에는 치료 후 24개월 이내에 질병 진행을 경험하는 POD24 환자를 위한 다중 모드 FL 데이터를 생성하는 데 중점을 두며, 이는 템퍼스가 후원하는 연구를 통해 이루어집니다. 이 데이터 라이브러리는 연구자들이 FL 생물학을 이해하는 데 도움이 되고 질병의 이질성에 대한 통찰력을 제공함으로써 정밀 의약품 개발을 지원할 것으로 기대됩니다.
이 파트너십은 FL에 대한 IFLI의 전문적인 초점과 템퍼스의 AI 지원 솔루션을 결합하여 모낭 림프종과 싸우는 연구자 및 전문가들이 접근할 수 있는 중앙 집중식 데이터베이스를 생성합니다.
Tempus AI (NASDAQ: TEM) a annoncé une collaboration avec l'Institute for Follicular Lymphoma Innovation (IFLI) pour développer une bibliothèque de données multimodales et déidentifiées sur le lymphome folliculaire (FL) au sein de la plateforme Lens de Tempus. L'initiative vise à accélérer le développement de thérapies ciblées pour les patients atteints de FL grâce à des informations alimentées par l'IA.
La collaboration se concentrera initialement sur la génération de données multimodales sur le FL pour les patients POD24 - ceux qui connaissent une progression de la maladie dans les 24 mois suivant le traitement - à travers une étude sponsorisée par Tempus. La bibliothèque de données devrait améliorer la compréhension des chercheurs sur la biologie du FL et soutenir le développement de médicaments de précision en fournissant des informations sur l'hétérogénéité de la maladie.
Le partenariat combine l'expertise spécialisée de l'IFLI sur le FL avec les solutions activées par IA de Tempus pour créer une base de données centralisée qui sera accessible aux chercheurs et aux professionnels s'efforçant de lutter contre le lymphome folliculaire.
Tempus AI (NASDAQ: TEM) gab eine Zusammenarbeit mit dem Institute for Follicular Lymphoma Innovation (IFLI) bekannt, um innerhalb der Tempus-Lens-Plattform eine realistische multimodale, anonymisierte Datenbibliothek über follikuläres Lymphom (FL) zu entwickeln. Die Initiative zielt darauf ab, die Entwicklung gezielter Therapien für FL-Patienten durch KI-gesteuerte Erkenntnisse zu beschleunigen.
Die Zusammenarbeit wird sich zunächst auf die Generierung multimodaler FL-Daten für POD24-Patienten konzentrieren – also Patienten, die innerhalb von 24 Monaten nach der Behandlung eine Krankheitsprogression erleben – im Rahmen einer von Tempus gesponserten Studie. Es wird erwartet, dass die Datenbibliothek das Verständnis der Forscher über die Biologie des FL verbessert und die Entwicklung von Präzisionsmedikamenten unterstützt, indem sie Einblicke in die Heterogenität der Krankheit bietet.
Die Partnerschaft kombiniert den spezialisierten FL-Fokus von IFLI mit den KI-gestützten Lösungen von Tempus, um eine zentrale Datenbank zu schaffen, die für Forscher und Fachleute, die gegen das follikuläre Lymphom kämpfen, zugänglich sein wird.
- Strategic collaboration with IFLI expands Tempus' presence in oncology research
- Development of new FL data library enhances Tempus' Lens platform capabilities
- Partnership provides access to specialized POD24 patient data
- None.
Insights
This strategic collaboration between Tempus and IFLI marks a pivotal advancement in the $4.5 billion follicular lymphoma market. The partnership leverages Tempus's AI capabilities to address a critical gap in FL treatment development, particularly focusing on high-risk POD24 patients who represent approximately 20% of FL cases and have significantly poorer outcomes.
The creation of a comprehensive FL data library through Tempus's Lens platform represents a substantial commercial opportunity. By establishing this specialized database, Tempus positions itself as a central hub for FL research, potentially generating multiple revenue streams through: 1) data licensing to pharmaceutical companies developing FL treatments, 2) AI-driven insights services, and 3) collaborative research partnerships.
The focus on POD24 patients is particularly strategic as this underserved population has treatment options, representing a high-value market segment. The real-world, multimodal data collection approach will provide pharmaceutical companies with invaluable insights for drug development, potentially accelerating the timeline from research to market approval.
This collaboration strengthens Tempus's competitive moat in several ways:
- Creates a unique, specialized FL database that competitors cannot easily replicate
- Establishes Tempus as a key player in FL research and development
- Enhances the company's AI capabilities through access to specialized oncology data
- Positions Tempus as an essential partner for pharmaceutical companies developing FL treatments
The partnership also demonstrates Tempus's ability to execute its platform expansion strategy, moving beyond general oncology data to create disease-specific databases that can command premium pricing in the precision medicine market. This specialization strategy could serve as a template for future collaborations in other rare or complex diseases, potentially multiplying the company's revenue opportunities across different therapeutic areas.
IFLI is committed to supporting advances in understanding the biology of FL patients who are at high risk of cancer progression and enhancing therapeutic development to address critical unmet needs in the management of this disease. The collaboration will initially focus on prospectively generating multimodal FL data, particularly for POD24 patients who experience disease progression within 24 months of treatment, through a Tempus-sponsored study.
The availability of a follicular lymphoma data library has the potential to improve researchers' understanding of the disease's biology. Providing researchers with access to robust multimodal data supports their work in uncovering critical insights into the heterogeneity of FL, which may lead to the development of more targeted precision medicines. A comprehensive understanding of the disease is crucial for tailoring treatments to individual patient profiles, enhancing outcomes, and advancing the fight against this complex disease.
“This collaboration exemplifies the power of combining IFLI’s specialized focus on FL with Tempus’ cutting-edge AI-enabled solutions,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “We are excited to work with IFLI and explore a new way of working with foundations to advance research. By leveraging our combined expertise and reach, we aim to create a centralized and dynamic data library that enables researchers to better understand FL.”
“IFLI is thrilled to announce our collaboration with Tempus, chosen for their exceptional leadership in the field. Together, we aim to create a robust, de-identified FL database, accelerating research and drug development to ultimately find a cure for the FL patient community,” said David McCullagh, Managing Director at IFLI. “ We believe Tempus is uniquely positioned to develop this comprehensive FL database, making it accessible to professionals in the field to combat this disease effectively.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
About the Institute for Follicular Lymphoma Innovation
The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research and for more information on IFLI, visit www.i-fli.org.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of the collaboration with IFLI. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213399761/en/
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What is the purpose of Tempus' collaboration with IFLI for follicular lymphoma research?
How will TEM's follicular lymphoma data library benefit researchers?
What is the initial focus of the Tempus-IFLI collaboration?
How will TEM's Lens platform be utilized in the IFLI collaboration?
